Inhaled Drug Delivery Conference: Industry Case Studies, Regulatory Updates, Latest Therapies and Technology Innovations - London, United Kingdom - November 6-7, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 14, 2019--
The “Inhaled Drug Delivery” conference has been added to ResearchAndMarkets.com’s offering
This seminar includes presentations and knowledge-sharing from world-recognised experts from industry, academia and regulation in the area of respiratory medicines and is an essential event for all those new to or experienced in inhaler drug delivery.
Inhaled drug delivery is achieved using four principal technologies: dry powder inhalers, metered-dose inhalers, nebulisers and liquid inhalers. Although there are many differences between these technologies, there are a number of fundamental principles that are followed to achieve an effective delivered dose. This event will provide an excellent forum to share knowledge and explore the opportunities across the dose forms with key industry leaders.
The most recent and innovative developments in inhaled drug delivery will be addressed including the use of triple therapies in lung disease, the development of long-awaited generic inhalers, the use of quality by design (QbD) principles in continuous manufacture, innovation in nebuliser treatment, reviews of connected devices, and the use of human factors in the design process. Regulations are key to respiratory medicines and future European and UK regulatory processes following Brexit will be critical when developing product approval strategies. Regulatory issues on this and other important hot topics will be considered.
This programme will provide valuable insights into inhaled drug delivery from experts in the field and will give you:
Benefits of attending
Programme Day One
Chair’s welcome and introduction
You can breathe easily now: modern respiratory medicines
Innovation in nebulised therapy
Dr John Pritchard
New concepts for inhaled corticosteroid therapeutic equivalence
INFORM 2020: new analytical insights into dry powder formulations for inhalation
Professor Darragh Murnane
Developing triple combination inhalers
Bringing better inhaled drugs faster to market through functional respiratory imaging (FRI) and artificial intelligence (AI)
- Facilitate the development of novel treatments in COPD
- Assist in tackling environmental challenges such as wildfire exposure
Jan de Backer
Digitally enabled inhalers - a clinician’s perspective
Technology transfer (TT) for inhaled drugs
Programme Day two
Review of day one
Review of new inhalation technologies
How to navigate a smooth regulatory pathway for inhaled products
Regulatory alignment between the UK and Europe post Brexit
Dr David Jefferys
Human factors (HF) studies - a hype or a must-do?
Handling fourses for the different use of inhaler devices
Dr Herbert Wachtel
Inhaler devices and the environment
Could smart inhalers dramatically change the way that asthma and COPD patients are treated?
Chair’s closing remarks
For more information about this conference visit https://www.researchandmarkets.com/r/ren1a
View source version on businesswire.com:https://www.businesswire.com/news/home/20191014005260/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 10/14/2019 05:36 AM/DISC: 10/14/2019 05:36 AM